A multicenter, open-label, pharmacokinetic/pharmacodynamic safety, and tolerability study of basiliximab (simulect) in pediatric de novo renal transplant recipients

Basiliximab (Simulect) has been shown to be safe and effective in adult renal transplant recipients, when used in combination with cyclosporine (Neoral) and corticosteroids. We report on the safety and preliminary efficacy of basiliximab in pediatric de novo renal transplant recipients. This was an...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Transplantation 2002-10, Vol.74 (7), p.961-966
Hauptverfasser:	OFFNER, Gisela, BROYER, Michel, KORN, Alexander, HALL, Michael, NIAUDET, Patrick, LOIRAT, Chantal, MENTSER, Mark, LEMIRE, Jacques, CROCKER, John F. S, COCHAT, Pierre, CLARK, Godfrey, CHODOFF, Lawrence
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adrenal Cortex Hormones - therapeutic use Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - pharmacokinetics Antibodies, Monoclonal - therapeutic use Azathioprine - therapeutic use Basiliximab Biological and medical sciences Child Child, Preschool Cohort Studies Cyclosporine - therapeutic use Drug Therapy, Combination Female Graft Rejection - epidemiology Graft Rejection - prevention & control Humans Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - adverse effects Immunosuppressive Agents - pharmacokinetics Immunosuppressive Agents - therapeutic use Incidence Infant Injections, Intravenous Kidney Transplantation - adverse effects Male Medical sciences Recombinant Fusion Proteins Safety Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Surgery of the urinary system Time Factors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Basiliximab (Simulect) has been shown to be safe and effective in adult renal transplant recipients, when used in combination with cyclosporine (Neoral) and corticosteroids. We report on the safety and preliminary efficacy of basiliximab in pediatric de novo renal transplant recipients. This was an open-label, 12-month study of basiliximab in 41 patients (2 cohorts:
ISSN:	0041-1337
DOI:	10.1097/00007890-200210150-00010